INTS

Intensity Therapeutics, Inc. (INTS) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.5/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 2.6 (Weak)

Revenue growth evidence is unavailable in the provided metrics, and negative ROIC suggests prior capital deployment has not yet translated into scalable revenue compounding versus peers.

Zero reported capex and R&D ratios imply limited reinvestment visibility, which weakens the company’s ability to fund durable product or market expansion relative to peers.

The absence of five-year revenue, EPS, and FCF CAGR data prevents confirmation of repeatable growth, leaving long-term compounding capacity materially less proven than stronger peers.

Negative enterprise-value and free-cash-flow metrics indicate the current business base is not yet generating the financial surplus typically needed to accelerate multi-year revenue expansion.

Market Tailwinds

Score:

No segment, concentration, or end-market data is provided, so there is no evidence of identifiable demand tailwinds supporting sustained revenue expansion versus peers.

The available metrics show financial underperformance rather than demand-led scaling, which implies weaker conversion of market opportunity into durable growth than peer companies.

Without disclosed customer or geography diversification, the company’s long-term growth capacity cannot be shown to benefit from broadening addressable demand more effectively than peers.

The data set offers no proof of structural market acceleration, so tailwind visibility remains low and does not support a higher growth profile.

Scalability Expansion

Score:

Negative ROIC and weak cash generation indicate reinvested capital has not produced efficient scaling, limiting the company’s ability to compound revenue faster than peers.

The very low or zero reported investment ratios suggest constrained evidence of scalable expansion capacity, especially versus peers that can reinvest into growth engines.

A negative cash-conversion cycle is unusual but, without supporting operating detail, it does not establish durable scalability or repeatable expansion advantages.

Leverage is present while interest coverage is zero, which can restrict future growth funding and reduce flexibility to scale relative to better-capitalized peers.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint, because it signals that incremental capital has not been compounding value or supporting durable revenue growth.

Zero interest coverage indicates financing fragility, which can cap reinvestment capacity and slow expansion more than in peers with stronger balance-sheet flexibility.

The lack of disclosed historical growth metrics creates a visibility constraint, making it difficult to evidence sustained compounding or scalable execution over time.

Weak profitability and leverage together suggest the company faces tighter structural limits to self-funded growth than peers with positive cash generation and coverage.

Overall Score

Score:

INTS shows weak long-term growth capacity because the provided metrics do not evidence repeatable revenue compounding, while negative ROIC and financing fragility constrain scalable reinvestment versus peers.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Intensity Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →